mole 4d4D-175 combines the customized and evolved intravitreal vector, R100, and a codon-optimized transgene encoding a hhly functional shortened form of human complement factor H (sCFH).The genetic medicine candidate is desned to4DMT is a clinical stage biopharma pany inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases.